RadNet’s Strategy Chief Shoots Up 1.2 M Shares in Zero‑Cost Options, Signaling Strong Insider Confidence in Growth Path

Insider Buying Surge Signals Confidence in RadNet’s Growth Path

RadNet Inc. has just reported a cluster of option‑exercising transactions by Chief Strategy Officer Alma Sorensen‑Gregory on March 10, 2026. Over 100,000 shares were bought in a single day, bringing her total holdings to roughly 1.23 million shares. The moves are all “exercise of previously granted option” and were completed at zero transaction price, a common practice when options vest. The cumulative volume represents about 0.1 % of the company’s outstanding shares, yet the sheer number of exercises—each a separate transaction—suggests a deliberate effort to increase ownership and lock in future upside.

Implications for Investors and Company Outlook

The timing of Gregory’s purchases coincides with a period of declining share price (the stock closed at $61.20, down 10.33 % over the week) and a broader industry shift toward digital health. Her buying spree is therefore interpreted as a bullish signal: the company’s highest‑level strategist is aligning her interests with shareholders and betting on the long‑term value of RadNet’s diagnostic and DeepHealth platforms. For investors, the move may reduce short‑term volatility and improve confidence in the management’s stewardship, especially as the firm is preparing to showcase its technology at the upcoming Barclays Global Healthcare Conference. From a valuation standpoint, the negative price‑earnings ratio and the company’s recent revenue growth imply that the stock is currently undervalued relative to its peers, making insider buying even more attractive.

What the Trend Tells About RadNet’s Future

Gregory’s historical activity—buying 16,533 shares in early March 2026 and selling 5,600 shares in June 2025—illustrates a balanced approach: she purchases when the firm is in a growth phase and divests when market conditions warrant. The recent series of exercises, all at zero cost, indicates confidence in the company’s trajectory rather than a need to raise capital. Combined with the strong insider activity across the board—executives such as President Howard Berger, COO Norman Hames, and EVP Katz David Jeffrey all increased their holdings in early March—RadNet’s top tier appears to be reinforcing its commitment to a strategy focused on expanding imaging services and digital health solutions. This alignment between senior management and shareholders can be a harbinger of future earnings growth, particularly as the company leverages its outpatient network and DeepHealth capabilities to capture a larger share of the growing diagnostic market.

Alma Sorensen‑Gregory: A Profile of Strategic Insider

Alma Gregory has served as EVP and Chief Science Officer before being promoted to Chief Strategy Officer. Her trading history shows a preference for options that vest over time, allowing her to build stake gradually without immediate market impact. She has historically purchased shares at low points (e.g., 5,600 shares sold in June 2025 at zero price, likely after a vesting event) and held significant positions that reflect a long‑term view. Her pattern of buying in March 2026 aligns with the company’s broader insider buying trend, suggesting she sees sustained value in RadNet’s growth initiatives and is willing to front‑load her position as the firm moves toward the next expansion phase. Her moves also correlate with the company’s recent announcement of a high‑profile conference appearance by CFO Mark Stolper, indicating that she is tracking strategic milestones closely.

Bottom Line for Market Participants

The cluster of option exercises by Alma Sorensen‑Gregory and the accompanying insider buying by other senior executives signal a collective confidence in RadNet’s strategic direction. For investors, these actions may serve as a positive barometer of management’s commitment and a potential catalyst for price recovery after a recent weekly decline. As RadNet continues to invest in digital health and expand its diagnostic footprint, the alignment of insider holdings with shareholder interests could translate into a more stable, growth‑oriented trajectory for the company.